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ABSTRACT 
 
The LC-ESI-MS was developed and validated for the analysis of imatinib in plasma 
and bone marrow samples using deuterated imatinib (D8-IM) as an internal standard. 
The biological samples were extracted using Strata-X-C SPE cartridges and separated 
on C8 column (50 x 3 mm, 3 µm), and methanol: 0.1% formic acid (70:30) was 
delivered at the rate of 0.7 ml/min as a mobile phase. Imatinib was quantified in 
samples by monitoring the ions m/z 494.3 for imatinib and 502.3 for D8-imatinib on 
mass spectrometer. The method was linear in the concentration range of 1-1500 
ng/250 µL in spiked human plasma samples and limit of quantification was 5 ng/mL. 
Inter-day and intra-day variations in spiked human plasma spiked with 50, 250 and 
500 ng /mL were less than 3.16%. The repeatability and reproducibility and other 
parameters of the methods were also validated. The method was employed for the 
analysis of the imatinib in human plasma and bone marrow samples. The drug levels 
in bone marrow and plasma samples were correlated to the degree of cytogenetic 
response. No significant difference of imatinib level between blood and bone marrow 
in IM-treated patients dosed to steady state was observed. 
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INTRODUCTION  
 
The selective Abl tyrosine kinase inhibitor, imatinib mesylate (IM; Gleevec or 
Glivec) has become the gold standard treatment of Chronic Myeloid Leukaemia 
(CML)1,2.  Discovered from a rational drug design program, IM blocks the activity of 
BCR-ABL, the oncogenic tyrosine kinase created by the Philadelphia (Ph) 
chromosome translocation diagnostic of CML.  Although clinical studies in the three 
sequential stages of the disease (chronic phase3, accelerated phase4, and terminal blast 
crisis5,6) confirm the substantial activity of the drug in vivo, responses are not 
sustained in advanced phases.  Further, the majority of patients in the early chronic 
phase do not achieve the deepest level of response, i.e. molecular remission that is 
polymerase chain reaction (PCR) negativity for BCR-ABL7. 
 
Knowing that CML is a clonal disease of stem cell origin, it has been postulated that 
low stem cell turnover in vivo may facilitate survival of ‘protected’ quiescent stem 
cells able to maintain and repopulate the disease8,9.  Physiologically, bone marrow is 
the major compartment for white cell production, and this is the compartment in 
which quiescent CML stem cells are presumed to reside.  In the face of emerging 
resistance it would be of interest to know the level of IM achieved in patient marrow.  
We sought to assess whether inadequate patient response was in part related to failure 
to achieve a sufficiently high IM level in bone marrow as compared to peripheral 
blood.  
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The aim of the present work was to relate drug levels to the clinical status of patients 
at the time of sampling using a suitably sensitive, precise and accurate method for the 
analysis of IM in peripheral blood and matched bone marrow plasma samples. 
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DESIGN AND METHODS  
 
Reagents and solutions 
Methanol, acetonitrile, high pressure liquid chromatography (HPLC) water, 98% v/v 
formic acid and 35% v/v ammonia solution (analytical reagent grade) were all 
obtained from BDH Laboratory Supplies (Poole, UK).  IM and the internal standard 
D8-IM were kind gifts from Novartis Pharma, Basle, Switzerland.  Stock IM and 
internal standard D8-IM solutions at 1mg/mL were prepared in 50:50 methanol:1% 
w/v formic acid and stored at +4ºC until use.  The stock solution was diluted for 
HPLC analysis with 1% w/v formic acid.   
 
Clinical samples 
Peripheral blood was drawn into ethylene diamine tetra-acetic acid (EDTA) tubes 
with informed consent from CML patients or healthy volunteers according to the 
Declaration of Helsinki.  Bone marrow aspirate, excess to clinical diagnostic 
requirements, was also harvested from the CML patients.  CML marrow was sampled 
at 3 or 4 months follow-up post-initiation of IM. The plasma supernatant was 
separated by centrifugation of whole blood at 1200rpm for 10 minutes and stored 
frozen at -20°C until required.  Glasgow Royal Infirmary Local Research Ethics 
Committee approved the use of human tissue in this study. 
 
Solid phase extraction (SPE) method for plasma and bone marrow samples 
Frozen peripheral blood or bone marrow plasma samples were thawed at room 
temperature.  0.25mL was transferred to a 1mL plastic vial to which was added 
0.25mL 0.1M phosphate buffer pH3.0 with an appropriate volume of internal standard 
solution.  The solution was vortex mixed for 30 seconds then transferred to a Strata-
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X-C column (Phenomenex, Macclesfield, UK) previously washed with 1mL of 
phosphate buffer.  The column was washed with 1mL water, 1mL methanol, and then 
twice eluted with 1mL of 2M ammonium hydroxide in methanol.  The eluent was 
collected, evaporated under a stream of nitrogen and dissolved in 0.1% w/v formic 
acid. 
 
High pressure liquid chromatography mass spectrometry (LC-MS) for analysis of 
IM in biological fluids  
IM analysis of plasma or bone marrow samples was performed using a Spectra 
Systems HPLC equipped with a P2000 pump, AS1000 autosampler with 20µL fixed 
injection loop and UV2000 detector (ThermoSeparations, Hemel Hempstead, Herts, 
UK).  Chromatographic separation was at ambient temperature using an ACE 3µm 
C8 column (50 x 3mm internal diameter; HiChrom, Reading, UK).  Mobile phase 
(methanol:formic acid 0.1% w/v) in the ratio of 70:30 was delivered in isocratic mode 
at a flow rate of 0.7mL / min over 10 minutes.   
 
Analytes were detected using an LCQ Finnigan Automass LC-MS system 
(ThermoSeparations).  Samples at 20µL were injected via the autosampler into the 
mass spectrometer without splitting at a flow rate of 0.7mL / min.  The interface was 
operated in positive ion electrospray mode at 4.5 kV.  The capillary temperature was 
adjusted to 270°C.  The MS data were acquired under selected ion monitoring mode 
by monitoring for the IM ion at m/z 494.3 and at 502.3 for D8-IM.  
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RESULTS AND DISCUSSION  
 
 
Based on our group’s research interest in persistent quiescent CML stem cells within 
the bone marrow compartment, we postulated that truly successful chemotherapeutic 
disease eradication may only be achieved if local drug delivery is optimal.  An 
investigation into the correlation of peripheral blood and bone marrow plasma drug 
levels was therefore planned for which a sensitive, precise and accurate analytical 
methodology had to be developed.   
 
Extraction of IM from biological samples using an SPE method proved to be superior 
to the solvent based approach of existing methods.11-13  Using the latter methodology, 
the poorest result was achieved with acetonitrile as the extraction solvent with only 
68% drug recovery in comparison to 89% ± 5% IM recovery by SPE (IM at 200ng in 
250µL, n = 5).  
 
The LC-MS analytical methodology proved to be both specific without interference 
from other peripheral blood or bone marrow plasma components, and sensitive with a 
limit of detection (LOD) of 5ng / 250µL of IM.  Method linearity was proven by 
direct injection of standards in the range 1ng to 500ng / 250µL mobile phase (7 data 
points) described by the regression equation y = -0.0245 + 0.00203x (r2 = 0.998). 
Method precision (expressed as co-efficient of variation, % CV) and accuracy were 
studied at IM concentrations of 50, 250 and 500ng / 250µL.  Results were entirely 
satisfactory with intra-day accuracy in the range 89% to 98%, and intra-day precision 
(% CV) ranging from 0.6% to 3.5%.  These results were reproducible in inter-day 
studies.  
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From a cohort of 10 CML patients enrolled in a clinical trial studying IM in chronic 
phase (Novartis studies 0106 and 0113), matched peripheral blood and bone marrow 
aspirate samples were processed to determine drug levels.  The average IM level in 
peripheral blood samples taken at 3 or 4 months post-initiation of IM therapy (Table 
1) was in keeping with published human pharmacokinetic data dosed to steady state10.  
At this time, all patients had achieved an haematological remission (to < 10 x 106 / 
mL). However, only half had achieved the next level of response that is a complete 
cytogenetic response (CCR).  None of the patients were PCR-negative for BCR-ABL 
at this stage.  
 
On analysis of total data from all patients, there was no significant difference in the 
average drug concentration between peripheral blood and bone marrow plasma. This 
suggests that 400mg IM daily is sufficient to sustain equilibrium between peripheral 
blood and bone marrow plasma at a therapeutic level (approximately 2 µM). When 
the levels measured in the cytogenetically responding patients were compared with 
the non-responders, there were still no significant differences between sub-groups in 
peripheral blood or bone marrow.  
 
In summary, using a sensitive assay for measurement of IM in biological samples, we 
have found that the IM concentration in peripheral blood and bone marrow plasma 
from CML patients dosed to steady state is in equilibrium. Despite the relatively 
limited patient numbers studied, these data were nonetheless consistent demonstrating 
good distribution of the drug into this previously un-assayed tissue. However, as we 
believe that higher intracellular levels of IM are required to kill stem cells than mature 
leucocytes in vitro, due to over-expression of BCR-ABL protein and / or multi-drug 
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resistance pumps14,15, we now hypothesise that more effective intracellular stem cell 
drug loading may be required within the bone marrow compartment.  
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TITLES AND LEGENDS  
 
Table 1.  Concentration of IM in matched bone marrow and plasma samples from 
treated CML patients at haematological remission (3 or 4 months). 
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Table 1.  Concentration of IM in matched bone marrow and plasma samples from 
treated CML patients at haematological remission (3 or 4 months) 
 
   IM Concentration (µmolar)   
Sample  n   Peripheral blood  Bone marrow   
All patients 10      1.64 ± 0.07      2.14 ± 0.08    
CCR    5      1.78 ± 0.21      2.15 ± 0.12   
No CCR  5      1.49 ± 0.12      2.13 ± 0.24  
 
